Curriculum Vitae

Updated on January 19, 2026

  • University of Illinois Chicago
  • Department of Pharmacy, Systems, Outcomes, and Policy
  • 833 S Wood St Room 246, Chicago IL, 60612
  • abdu.i.aziz@outlook.com
  • aabdel51@uic.edu

Summary

Health outcomes reaseach scientist / Health data scientist data scientist specializing in Real-World Data (RWD) study execution—turning research questions into analysis-ready cohorts, validated variables, reproducible programs, and decision-ready results. Experienced leading end-to-end observational analyses across claims-linked and registry-style data, with strong emphasis on analysis specifications, technical documentation, quality control, and transparent reporting. Published in peer-reviewed journals (oncology, drug safety, HEOR) and proficient in R, SAS, SQL, and Python.

Core Skills

  • Statistical Programming (Independent delivery): R, SAS, SQL, Python
  • RWD Study Execution: cohort construction (eligibility/exposure/outcomes/covariates), variable operationalization, data validation checks, analytic dataset generation
  • Analysis Specifications & Technical Documentation: reproducible analysis plans/specs, codebooks/derivations, endpoint definitions, traceable outputs
  • Observational Methods: cohort study design, survival/time-to-event, regression/GLMs, predictive modeling; causal inference / target trial emulation concepts
  • Quality Control & Standards: structured QA checks, unit testing (pytest, testthat), code review practices, version control
  • Healthcare Data: SEER-Medicare, MarketScan, SEER, NHANES, BRFSS, Optum
  • Data Engineering for RWD: DuckDB, Arrow/Parquet, Git/GitHub, automated reporting (Quarto)
  • Visualization & Communication: Shiny, Dash, Tableau; translating complex results for non-technical audiences
  • Familiar / Exposure: Docker (basic), AWS (basic)

Education

Doctor of Philosophy – Pharmacy Systems Outcomes and Policy
University of Illinois Chicago Aug 2020 — Present

Master of Science – Pharmacy Systems Outcomes and Policy
University of Illinois Chicago May 2023 — Dec 2023

Bachelors of Pharmacy
Faculty of Pharmacy, Minia University Sep 2012 — May 2017

  • Excellent (Distinction with Honors.)
  • Rank: 4/320

Work experience

Data Scientist

EntityRisk May 2025 – Present

  • Lead development of technical requirements and analysis logic for internal evidence-generation software supporting budget impact modeling workflows.
  • Build and maintain reproducible program components in Python/R/SQL using modular, reusable code patterns aligned to evolving stakeholder requirements.
  • Establish quality expectations through unit tests (pytest), documentation, and structured version control to support reliable delivery.
  • Collaborate cross-functionally to translate decision needs into traceable assumptions, outputs, and reporting deliverables.

Research Analyst (Health Outcomes & Data Science)

University of Illinois Chicago Apr 2023 – Present

  • Lead day-to-day RWD analysis execution: define eligibility/exposure/outcomes/covariates; build analytic cohorts; and deliver reproducible analyses.
  • Develop analysis specifications (variable derivations, cohort logic, endpoint definitions) and implement them in code to generate analysis-ready datasets.
  • Apply statistical methods including time-to-event models and regression/GLMs, producing stakeholder-ready tables/figures and written interpretation.
  • Implement pragmatic QC checks (logic validation, data consistency checks, reproducibility checks) to maintain methodological rigor across deliverables.
  • Contribute to protocol/manuscript development and cross-functional collaboration with clinical/research stakeholders.

Research Associate

Department of Clinical Pharmacy-University of Southern California May 2023 – Aug 2023

  • Contributed to research evaluating prescription medication use with potential carcinogenic effects in the United States using NHANES.
  • Supported reproducible data preparation and analysis workflows to produce research-ready outputs.

Pharmacoepidemiology Ph.D. summer intern

Regeneron Pharmaceuticals May 2022 — Aug 2022

  • Evaluated treatment patterns among smoldering multiple myeloma patients.
  • Produced analysis outputs to support clinical and epidemiologic interpretation.

Research Assistant

University of Illinois Chicago Aug 2020 – Mar 2023

Real-World Evidence / Outcomes Research

Supported multiple projects by designing real-world studies, building analytic cohorts, developing screening algorithms, optimizing analysis workflows, running statistical analyses, and writing reports and manuscripts. Projects include:

  • Estimating the Concordance of Treatment Effects Between Randomized Controlled Trials (RCTs) and Real-World Replications in Oncology: A Systematic Review and Meta-Analysis
  • Adherence to Prescription Proton Pump Inhibitor Therapy in Individuals Diagnosed with Barrett’s Esophagus
  • Factors associated with oseltamivir dispensing for high-risk of influenza complications in children: A retrospective cohort study using commercial claims
  • A High-throughput Drug Safety Signal Detection of Roflumilast Using Sequence Symmetry Analysis (2011-2021)
  • Pathologic complete response among non-metastatic esophageal carcinoma patients who received neoadjuvant therapy: a systematic review and meta-analysis

Health Economics and Decision Modeling

Supported projects by systematically reviewing the literature and collecting model inputs, implementing decision models (decision trees, Markov models, and microsimulation), improving model performance and reproducibility in R, and writing reports and manuscripts. Projects include:

  • Cost-effectiveness and budget impact analysis of Artificial Intelligence-driven risk stratification in US Veterans with diabetic kidney disease (DKD)

Health Policy and Pharmacy Practice

Supported projects by preparing IRB protocols, conceptualizing study goals and study design, and data cleaning and analysis. Projects include:

  • The effect of the removal of sobriety restriction for hepatitis C virus treatment access on sustained virologic response in U.I. Health patients
  • Estimation of potential cost savings from alternative reimbursement models for clinician-administered drugs among Medicare cancer patients

Selected Publications

\(\text{*}\)indicates first or co-first authorship
**indicates corresponding authorship

Full publication list: Google Scholar

  • Sarker J*, Abdelaziz AI*, Crook J, Nelson RE, LaFleur J, Nyman H, Lu C-C, Kim K. Cost-Effectiveness Analysis of Artificial Intelligence-Driven Risk-Stratification in Patients With Diabetic Kidney Disease in the US Veterans Population. Kidney Medicine. 2026;101261. [Link]
  • Abdelaziz A*, Winn AN, Dusetzina SB, Mitchell AP. Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market. JAMA Netw Open. 2025;8(11):e2542937. [Link]
  • Mitchell, A. P., Dusetzina, S. B., Meza, A. M., Gallagher, G., Augello, P., Fuchs, H., Guzman, G., Abdelaziz, A., Tabatabai, S., Persaud, S., Chakraborty, N., Blinder, V. S., Epstein, A. S., Daly, B., Winn, A. N., & Gönen, M. (2025). Provider billing margin and cancer treatment selection: Population based cohort study. BMJ, 391, e084729. [Link]
  • Abdullah Abdelaziz*, Jyotirmoy Sarker, Pei-Wen Lien, Derek J. Williams, Carlos G. Grijalva, Todd A. Lee, James W. Antoon, Factors Associated with Antiviral Drug Use Among Commercially Insured Children at High Risk for Complications of Influenza, The Journal of Pediatrics, Volume 282, 2025, 114574. [Link]
  • Abdelaziz, A.**, Gaber, C., Gupta, P. and Lee, T. (2025), High Throughput Pharmacovigilance Screening for Roflumilast Adverse Effects in Real-World Settings: A Sequence Symmetry Analysis. Basic Clin Pharmacol Toxicol, 136: e70038. [Link]
  • Abdelaziz AI**, Hanson KA, Gaber CE, Lee TA. Optimizing large real-world data analysis with parquet files in R: A step-by-step tutorial. Pharmacoepidemiol Drug Saf. 2023; 1-9. [Link]

Honors and Awards

ISPE Student Chapter Award (1st Place), UIC College of Pharmacy Research Day 2023
Edward Benes Scholarship 2022
UIC Travel Award for PhD Students (TAPS) 2022

Professional Affiliations

ASCO – American Society of Clinical Oncology (Member) Since 2019
AACR – American Association for Cancer Research (Associate Member) Since 2022
ISPE – International Society of Pharmacoepidemiology (Member) Since 2022
SER – Society for Epidemiologic Research (Member) Since 2022
ISPOR - The Professional Society for Health Economics and Outcomes Research (Member) Since 2021
SCI - Society for Causal Inference (Member) Since 2022
Egyptian Pharmacists Syndicate Since 2018

ISPOR (Member), ISPE (Member), ASCO (Member), AACR (Associate Member), Society for Causal Inference (Member)